1. Home
  2. MTH vs CRSP Comparison

MTH vs CRSP Comparison

Compare MTH & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTH
  • CRSP
  • Stock Information
  • Founded
  • MTH 1985
  • CRSP 2013
  • Country
  • MTH United States
  • CRSP Switzerland
  • Employees
  • MTH N/A
  • CRSP N/A
  • Industry
  • MTH Homebuilding
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MTH Consumer Discretionary
  • CRSP Health Care
  • Exchange
  • MTH Nasdaq
  • CRSP Nasdaq
  • Market Cap
  • MTH 4.9B
  • CRSP 4.2B
  • IPO Year
  • MTH 1988
  • CRSP 2016
  • Fundamental
  • Price
  • MTH $73.00
  • CRSP $59.12
  • Analyst Decision
  • MTH Buy
  • CRSP Buy
  • Analyst Count
  • MTH 10
  • CRSP 16
  • Target Price
  • MTH $74.42
  • CRSP $71.20
  • AVG Volume (30 Days)
  • MTH 901.2K
  • CRSP 3.5M
  • Earning Date
  • MTH 07-23-2025
  • CRSP 08-04-2025
  • Dividend Yield
  • MTH 2.47%
  • CRSP N/A
  • EPS Growth
  • MTH N/A
  • CRSP N/A
  • EPS
  • MTH 9.89
  • CRSP N/A
  • Revenue
  • MTH $6,284,888,000.00
  • CRSP $37,675,000.00
  • Revenue This Year
  • MTH $3.99
  • CRSP $30.25
  • Revenue Next Year
  • MTH $7.59
  • CRSP $268.62
  • P/E Ratio
  • MTH $7.04
  • CRSP N/A
  • Revenue Growth
  • MTH N/A
  • CRSP N/A
  • 52 Week Low
  • MTH $59.27
  • CRSP $30.04
  • 52 Week High
  • MTH $106.99
  • CRSP $63.68
  • Technical
  • Relative Strength Index (RSI)
  • MTH 61.22
  • CRSP 83.65
  • Support Level
  • MTH $67.88
  • CRSP $50.26
  • Resistance Level
  • MTH $73.01
  • CRSP $53.08
  • Average True Range (ATR)
  • MTH 2.41
  • CRSP 2.78
  • MACD
  • MTH 0.57
  • CRSP 0.93
  • Stochastic Oscillator
  • MTH 88.19
  • CRSP 98.13

About MTH Meritage Homes Corporation

Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising ten states: Arizona, California, Colorado, Texas, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Utah. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the homebuilding segment.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: